In light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?
From your perspective as both an IC and lipid medicine specialist, in light of the recent results showing a reduction in associated all-cause mortality in the ODYSSEY Outcomes Trial, which patients deserve our greatest attention to optimize the translational impact of this study?
Created by
Presenter
J. Wouter Jukema, MD, PhD, FESC, FACC MC
Professor of Cardiology
Netherlands Heart Foundation
Chairman, Leiden Vascular Medicine
Leiden University Medical Center (LUMC)
Leiden, Netherlands